Sign In
Buy AZN
$183.02
+2.00 (+1.10%)
At Close: Jun 24, 2026
London, UK, 7 October 2024 – Avillion Life Sciences Ltd (“Avillion”) announces that the ongoing BATURA Phase IIIb trial evaluating AstraZeneca's Airsupra (albuterol/budesonide) in patients with
AstraZeneca's Calquence sNDA Gets FDA Priority Tag for Expanded Use
12:51pm, Thursday, 03'rd Oct 2024
The FDA grants priority review to AZN's sNDA for Calquence for untreated mantle cell lymphoma. A decision is expected in first-quarter 2025.
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p
Owkin Announces Partnership with AstraZeneca to Develop an AI gBRCA Pre-Screen Solution for Breast Cancer
03:00am, Wednesday, 02'nd Oct 2024
PARIS--(BUSINESS WIRE)--Owkin, the first end-to-end AI-biotech that uses cutting-edge causal AI to unlock precision drug discovery, development and diagnostics, is pleased to announce a new partnershi
AstraZeneca's Enhertu sBLA Gets FDA Priority Tag for Expanded Use
01:00pm, Tuesday, 01'st Oct 2024
The FDA grants priority review to AZN's sBLA for Enhertu to treat HER2-low or HER2-ultralow metastatic breast cancer. A decision is due in first-quarter 2025.
AstraZeneca Stock Up Almost 14% in 6 Months: Time to Buy?
04:01pm, Thursday, 26'th Sep 2024
AZN's key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Farxiga are likely to drive sales. It has several candidates with blockbuster potential.
AZN's Tagrisso Gets FDA Nod for Expanded Use in NSCLC
01:11pm, Thursday, 26'th Sep 2024
The FDA approves AstraZeneca's Tagrisso for treating unresectable, stage III EGFR-mutated non-small cell lung cancer.
Buy These 5 Big Drug Stocks to Boost Your Portfolio's Health
10:41am, Thursday, 26'th Sep 2024
Pfizer, Eli Lilly, AstraZeneca, Bayer and Sanofi can prove to be great additions to your portfolio.
AstraZeneca in AI collaboration with Immunai to inform cancer drug trials
09:06am, Thursday, 26'th Sep 2024
AstraZeneca will pay $18 million to biotechnology firm Immunai Inc to use the New York-based firm's AI model of the immune system to make certain cancer drug trials more efficient, the latter said on
AZN Stock Slips as Dato-DXd Cancer Study Misses Survival Goal
04:02pm, Tuesday, 24'th Sep 2024
AZN's Daiichi Sankyo-partnered datopotamab deruxtecan fails to show overall survival benefits in a breast cancer study. Stock falls.
AstraZeneca PLC (AZN) Annual Deutsche Bank Leveraged Finance Conference (Transcript)
01:42pm, Tuesday, 24'th Sep 2024
AstraZeneca PLC (NASDAQ:AZN ) Deutsche Bank's Depositary Receipts Virtual Investor Conference September 24, 2024 11:30 AM ET Company Participants Elizabeth Walton - Director, Investor Relations Confer
CHMP Endorses AstraZeneca's Fasenra in Rare Autoimmune Disease
12:50pm, Tuesday, 24'th Sep 2024
If approved, AZN's Fasenra will be the second biologic approved in the European Union to treat eosinophilic granulomatosis with polyangiitis.
AstraZeneca: Buy This Big Pharma Stock At A Discount Now
08:00am, Tuesday, 24'th Sep 2024
AstraZeneca possesses all the key qualities of a qualitative dividend stock. The company topped the analyst consensus for net revenue and matched the analyst consensus for core EPS in Q2. AstraZeneca
AstraZeneca Stock Falls After Disappointing Results in Breast Cancer Drug Trial
11:33am, Monday, 23'rd Sep 2024
British drugmaker AstraZeneca (AZN) said Monday that a Phase 3 trial of a developmental drug failed to achieve "statistical significance" in improving the length of time patients with certain types of
AstraZeneca Dips On Surprise Miss For Gilead-Rivaling Cancer Drug
09:38am, Monday, 23'rd Sep 2024
AstraZeneca stock slumped Monday after its Daiichi Sankyo-partnered drug missed its mark in a study of patients with breast cancer.
